Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate and nebivolol hydrochloride, the active ingredients in Nesyrgy, are a calcium‑channel blocker and a selective β1‑adrenergic antagonist presented as an oral tablet for oral use. The combination is indicated for the treatment of hypertension in adult patients, providing convenient blood‑pressure control.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured batches and reliable logistics for global distribution. The company adheres to stringent regulatory standards and provides technical support to its partners.

Nesyrgy, a combination antihypertensive, acts on vascular resistance and cardiac output to lower blood pressure.

- Hypertension: lowers both systolic and diastolic blood pressure in adults. - Essential hypertension: provides sustained blood‑pressure control as part of combination therapy. - High‑risk hypertension: contributes to reduction of cardiovascular events when used with lifestyle measures.

Adverse reactions may occur with any antihypertensive therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after standing. - Flushing: transient warmth and redness. - Fatigue: general tiredness. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Bradycardia: markedly slow heart rate. - Severe hypotension: dangerous drop in blood pressure. - Hepatic dysfunction: abnormal liver enzymes. - Angioedema: swelling of face, lips, or throat. - Heart block: impaired electrical conduction. - Anaphylactic reaction: life‑threatening allergy.

Patients should be monitored for safety and efficacy before and during treatment.

- Blood pressure monitoring: check regularly to avoid excessive lowering. - Cardiac assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Concomitant beta‑blockers: avoid duplicate therapy unless medically justified. - Hepatic impairment: use with caution and adjust dose if needed. - Abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original pack, protect from moisture.

Drug‑interaction assessment is essential to prevent additive effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase amlodipine exposure. - Other beta‑blockers: risk of excessive bradycardia and hypotension. - Non‑dihydropyridine calcium channel blockers: can cause profound cardiac depression. - Potent CYP2D6 inhibitors (e.g., fluoxetine): may raise nebivolol levels. - Combined use with other antihypertensives: may lead to severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood‑pressure lowering effect. - NSAIDs: can blunt antihypertensive response. - Digoxin: may increase risk of bradycardia. - Antiplatelet agents: monitor for bleeding risk. - Alcohol: may potentiate hypotensive effect.